Nanocapsules embedded in microparticles for enhanced oral bioavailability and efficacy of Lopinavir as an anti-AIDS drug

Taher Nassar; Ayala Rohald; Natalya Naraykin; Dinorah Barasch; Orit Amsalem; Ponnandy Prabhu; Moshe Kotler; Simon Benita

doi:10.1080/1061186X.2018.1552275

Nanocapsules embedded in microparticles for enhanced oral bioavailability and efficacy of Lopinavir as an anti-AIDS drug

Taher Nassar, Ayala Rohald, Natalya Naraykin, Dinorah Barasch, Orit Amsalem, Ponnandy Prabhu, Moshe Kotler, Simon Benita^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

Lopinavir (LPV), an efficient drug for HIV infection treatment, was incorporated into biodegradable PLGA nanocapsules (NCs) embedded in microparticles (MCPs) using the spray-drying technique in an attempt to bypass the P-gp efflux and protect the drug from CYP3A pre-systemic metabolism without ritonavir (RTV). SEM observations confirmed the formation of NCs and their entrapment in the MCPs. LPV-loaded NCs and free LPV were released from the MCPs at pH of 7.4 as evidenced by in vitro release studies. Results obtained from rat studies showed a two-fold higher bioavailability of LPV following oral administration of the optimal formulation than Kaletra^®, the marketed drug, showing that when properly entrapped, LPV can be effectively protected from CYP degradation in the gut as well as from the liver following systemic absorption. It was also shown that serum derived from rats following LPV oral administration in two formulations and Kaletra^® significantly decreased the multiplication of HIV-1 in cultured SupT1 cells. Furthermore, the LPV formulations markedly restricted the titre of infectious HIV-1 production compared with Kaletra^® confirming the improved antiviral activity of LPV delivered in the rat blood circulation by the nanocapsules embedded in microparticle formulations.

Original language	American English
Pages (from-to)	590-600
Number of pages	11
Journal	Journal of Drug Targeting
Volume	27
Issue number	5-6
DOIs	https://doi.org/10.1080/1061186X.2018.1552275
State	Published - 3 Jul 2019

Bibliographical note

Funding Information:
All the remaining work has been supported by the Gattefosse Foundation, Lyon, France, The Kahn Foundation, Tel Aviv, Israel, and the Rosetrees Trust, Edgware, UK. Simon Benita would like to thank all these foundations for their kind donations and generosity.

Funding Information:
The in vitro antiviral work was carried out in the Peter A. Krueger Laboratory with the generous support of Nancy and Lawrence Glick and Pat and Marvin Weiss. Dr Ponnandy Prabhu is a fellow of PBC (for outstanding Post-Doctoral Researchers from India) of the Council for Higher Education in Israel. This work was supported in part by an NIH grant (P01 GM091743).

Publisher Copyright:
© 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group.

Keywords

HIV
Lopinavir
antiviral
bioavailability
microparticles
nanocapsules
oral

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/1061186X.2018.1552275

Cite this

@article{f323f6a85c7742adbe6b1eb6cf108fee,

title = "Nanocapsules embedded in microparticles for enhanced oral bioavailability and efficacy of Lopinavir as an anti-AIDS drug",

abstract = "Lopinavir (LPV), an efficient drug for HIV infection treatment, was incorporated into biodegradable PLGA nanocapsules (NCs) embedded in microparticles (MCPs) using the spray-drying technique in an attempt to bypass the P-gp efflux and protect the drug from CYP3A pre-systemic metabolism without ritonavir (RTV). SEM observations confirmed the formation of NCs and their entrapment in the MCPs. LPV-loaded NCs and free LPV were released from the MCPs at pH of 7.4 as evidenced by in vitro release studies. Results obtained from rat studies showed a two-fold higher bioavailability of LPV following oral administration of the optimal formulation than Kaletra{\textregistered}, the marketed drug, showing that when properly entrapped, LPV can be effectively protected from CYP degradation in the gut as well as from the liver following systemic absorption. It was also shown that serum derived from rats following LPV oral administration in two formulations and Kaletra{\textregistered} significantly decreased the multiplication of HIV-1 in cultured SupT1 cells. Furthermore, the LPV formulations markedly restricted the titre of infectious HIV-1 production compared with Kaletra{\textregistered} confirming the improved antiviral activity of LPV delivered in the rat blood circulation by the nanocapsules embedded in microparticle formulations.",

keywords = "HIV, Lopinavir, antiviral, bioavailability, microparticles, nanocapsules, oral",

author = "Taher Nassar and Ayala Rohald and Natalya Naraykin and Dinorah Barasch and Orit Amsalem and Ponnandy Prabhu and Moshe Kotler and Simon Benita",

note = "Funding Information: All the remaining work has been supported by the Gattefosse Foundation, Lyon, France, The Kahn Foundation, Tel Aviv, Israel, and the Rosetrees Trust, Edgware, UK. Simon Benita would like to thank all these foundations for their kind donations and generosity. Funding Information: The in vitro antiviral work was carried out in the Peter A. Krueger Laboratory with the generous support of Nancy and Lawrence Glick and Pat and Marvin Weiss. Dr Ponnandy Prabhu is a fellow of PBC (for outstanding Post-Doctoral Researchers from India) of the Council for Higher Education in Israel. This work was supported in part by an NIH grant (P01 GM091743). Publisher Copyright: {\textcopyright} 2018, {\textcopyright} 2018 Informa UK Limited, trading as Taylor & Francis Group.",

year = "2019",

month = jul,

day = "3",

doi = "10.1080/1061186X.2018.1552275",

language = "American English",

volume = "27",

pages = "590--600",

journal = "Journal of Drug Targeting",

issn = "1061-186X",

publisher = "Informa Healthcare",

number = "5-6",

}

TY - JOUR

T1 - Nanocapsules embedded in microparticles for enhanced oral bioavailability and efficacy of Lopinavir as an anti-AIDS drug

AU - Nassar, Taher

AU - Rohald, Ayala

AU - Naraykin, Natalya

AU - Barasch, Dinorah

AU - Amsalem, Orit

AU - Prabhu, Ponnandy

AU - Kotler, Moshe

AU - Benita, Simon

N1 - Funding Information: All the remaining work has been supported by the Gattefosse Foundation, Lyon, France, The Kahn Foundation, Tel Aviv, Israel, and the Rosetrees Trust, Edgware, UK. Simon Benita would like to thank all these foundations for their kind donations and generosity. Funding Information: The in vitro antiviral work was carried out in the Peter A. Krueger Laboratory with the generous support of Nancy and Lawrence Glick and Pat and Marvin Weiss. Dr Ponnandy Prabhu is a fellow of PBC (for outstanding Post-Doctoral Researchers from India) of the Council for Higher Education in Israel. This work was supported in part by an NIH grant (P01 GM091743). Publisher Copyright: © 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group.

PY - 2019/7/3

Y1 - 2019/7/3

N2 - Lopinavir (LPV), an efficient drug for HIV infection treatment, was incorporated into biodegradable PLGA nanocapsules (NCs) embedded in microparticles (MCPs) using the spray-drying technique in an attempt to bypass the P-gp efflux and protect the drug from CYP3A pre-systemic metabolism without ritonavir (RTV). SEM observations confirmed the formation of NCs and their entrapment in the MCPs. LPV-loaded NCs and free LPV were released from the MCPs at pH of 7.4 as evidenced by in vitro release studies. Results obtained from rat studies showed a two-fold higher bioavailability of LPV following oral administration of the optimal formulation than Kaletra®, the marketed drug, showing that when properly entrapped, LPV can be effectively protected from CYP degradation in the gut as well as from the liver following systemic absorption. It was also shown that serum derived from rats following LPV oral administration in two formulations and Kaletra® significantly decreased the multiplication of HIV-1 in cultured SupT1 cells. Furthermore, the LPV formulations markedly restricted the titre of infectious HIV-1 production compared with Kaletra® confirming the improved antiviral activity of LPV delivered in the rat blood circulation by the nanocapsules embedded in microparticle formulations.

AB - Lopinavir (LPV), an efficient drug for HIV infection treatment, was incorporated into biodegradable PLGA nanocapsules (NCs) embedded in microparticles (MCPs) using the spray-drying technique in an attempt to bypass the P-gp efflux and protect the drug from CYP3A pre-systemic metabolism without ritonavir (RTV). SEM observations confirmed the formation of NCs and their entrapment in the MCPs. LPV-loaded NCs and free LPV were released from the MCPs at pH of 7.4 as evidenced by in vitro release studies. Results obtained from rat studies showed a two-fold higher bioavailability of LPV following oral administration of the optimal formulation than Kaletra®, the marketed drug, showing that when properly entrapped, LPV can be effectively protected from CYP degradation in the gut as well as from the liver following systemic absorption. It was also shown that serum derived from rats following LPV oral administration in two formulations and Kaletra® significantly decreased the multiplication of HIV-1 in cultured SupT1 cells. Furthermore, the LPV formulations markedly restricted the titre of infectious HIV-1 production compared with Kaletra® confirming the improved antiviral activity of LPV delivered in the rat blood circulation by the nanocapsules embedded in microparticle formulations.

KW - HIV

KW - Lopinavir

KW - antiviral

KW - bioavailability

KW - microparticles

KW - nanocapsules

KW - oral

UR - http://www.scopus.com/inward/record.url?scp=85058816021&partnerID=8YFLogxK

U2 - 10.1080/1061186X.2018.1552275

DO - 10.1080/1061186X.2018.1552275

M3 - Article

C2 - 30470150

AN - SCOPUS:85058816021

SN - 1061-186X

VL - 27

SP - 590

EP - 600

JO - Journal of Drug Targeting

JF - Journal of Drug Targeting

IS - 5-6

ER -

Nanocapsules embedded in microparticles for enhanced oral bioavailability and efficacy of Lopinavir as an anti-AIDS drug

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this